Minimal Ablative Margin Quantification Using Hepatic Arterial Versus Portal Venous Phase CT for Colorectal Metastases Segmentation: A Dual-center, Retrospective Analysis.

Abstract

Objective: To compare the predictive value of minimal ablative margin (MAM) quantification using tumor segmentation on intraprocedural contrast-enhanced hepatic arterial (HAP) versus portal venous phase (PVP) CT on local outcomes following percutaneous thermal ablation of colorectal liver metastases (CRLM).

Methods: This dual-center retrospective study included patients undergoing thermal ablation of CRLM with intraprocedural preablation and postablation contrast-enhanced CT imaging between 2009 and 2021. Tumors were segmented in both HAP and PVP CT phases using an artificial intelligence-based auto-segmentation model and reviewed by a trained radiologist. The MAM was quantified using a biomechanical deformable image registration process. The area under the receiver operating characteristic curve (AUROC) was used to compare the prognostic value for predicting local tumor progression (LTP).

Results: Among 81 patients (60 y±13, 53 men), 151 CRLMs were included. During 29.4 months of median follow-up, LTP was noted in 24/151 (15.9%). Median tumor volumes on HAP and PVP CT were 1.7 mL and 1.2 mL, respectively, with respective median MAMs of 2.3 and 4.0 mm (both P< 0.001). The AUROC for 1-year LTP prediction was 0.78 (95% CI: 0.70-0.85) on HAP and 0.84 (95% CI: 0.78-0.91) on PVP (P= 0.002).

Conclusions: During CT-guided percutaneous thermal ablation, MAM measured based on tumors segmented on PVP images conferred a higher predictive accuracy of ablation outcomes among CRLM patients than those segmented on HAP images, supporting the use of PVP rather than HAP images for segmentation during ablation of CRLMs.